ReviewFrontiers in oncology2026
The research progress of the synergistic effect of Epstein-Barr virus and
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) is a malignant tumor characterized by high morbidity and mortality rates worldwide. The development of GC is a complex process influenced by various factors. Helicobacter pylori (HP) and Epstein-Barr virus (EBV) are recognized as pivotal contributors to this malignancy. HP instigates chronic inflammation, disrupts the gastric mucosal barrier, and triggers epigenetic modifications and aberrant cell signaling pathways, thereby facilitating GC progression. Conversely, EBV infection is specifically associated with Epstein-Barr virus-associated gastric cancer (EBVaGC), a distinct subtype of GC. EBV contributes to tumorigenesis by expressing latent membrane proteins, EBV nuclear antigens, and non-coding RNA, resulting in the hypermethylation of tumor suppressor genes in host cells and the rewiring of cellular metabolism. Historically, HP and EBV infections were considered distinct risk factors for gastric cancer. Nevertheless, recent research indicates a synergistic relationship between these pathogens in gastric cancer development, wherein they collaboratively influence key signaling pathways, bolster gastric cancer stem cell characteristics, and remodel the tumor microenvironment to expedite tumor advancement. The inflammatory milieu induced by HP infection fosters EBV colonization and reactivation. Consequently, comprehending the combined mechanism of gastric cancer initiation by EBV and HP infections holds paramount importance for gastric cancer treatment and prevention. This review comprehensively examines the synergistic interplay of HP and EBV in gastric cancer onset and progression, consolidates recent advancements in relevant research models and therapeutic approaches, and outlines prospective research avenues in this domain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.